SQUAWK/NEWS
Account
Theme
Account
Menu
Live News REGULATION FLASH L impact

Eton Pharmaceuticals Launches ET-900 Program for Epileptic Spasms

Eton Pharmaceuticals launched ET-900, evaluating mecasermin for infantile and epileptic spasms, with a Phase 2 study planned.Key Highlights:Original SEC Filing: Eton Pharmaceuticals, Inc. [ ETON ] - 8-K - Nov. 02, 2026This is an AI-powered summary. It may contain inaccuracies. Consider verifying im…

ETON
SquawkNews Desk

Related stories

Hangzhou SDIC Microelectronics and Controlling Shareholder Probed by Regulator The company says it and its controlling shareholder are under investigation over suspected information disclosure violations. L impact | REGULATION | Nov 02, 2026, 01:41 PM UTC FDA Places Bright Minds Biosciences Seizure Drug Application on Partial Hold Bright Minds Biosciences said the FDA placed its drug application and planned trial for a seizure treatment on partial clinical hold following a review. The stock fell 36% to $35 i M impact | REGULATION | Nov 02, 2026, 01:19 PM UTC NRx Pharmaceuticals Receives FDA Approval for Preservative-Free Ketamine NRx Pharmaceuticals said the FDA approved its preservative-free ketamine application ahead of the agency’s November 10 goal date. M impact | REGULATION | Nov 02, 2026, 01:13 PM UTC UniQure Says FDA Accepts Application for Huntington’s Gene Therapy UniQure said the FDA accepted an application for its potential Huntington’s disease gene therapy. L impact | REGULATION | Nov 02, 2026, 01:06 PM UTC Catheter Precision Announces FDA 510(k) Clearance for VIVO System The clearance enables use of the VIVO system in a broader patient population. L impact | REGULATION | Nov 02, 2026, 01:05 PM UTC Lupin Receives U.S. FDA Approval for Amifampridine Tablets M impact | REGULATION | Nov 02, 2026, 12:34 PM UTC